Our Board of Directors has a broad range of expertise, including company management, financial acumen and product development.
Dr. Samuel Waksal is the Founder, Chairman, Chief Executive Officer and President of Équilibre Biopharmaceuticals Corp. Prior to founding Équilibre, Dr. Waksal founded ImClone Systems – the developer of Erbitux, as well as Cyramza, the first anti-VEGFR-2 antibody – serving as its Chief Executive Officer and President. ImClone Systems was acquired by Eli Lilly & Company in 2008. Dr. Waksal is responsible for four cancer-field antibodies available on the global market, as well as many others currently in clinical trials.
In 2015, Dr. Waksal founded MeiraGTx (NYSE: MGTX), a London- and New York-based company, which focused on gene regulation, ocular gene therapy, xerostomia, and neurodegeneration. He was also a founding director of Medicis Pharmaceuticals, a dermatology company, acquired by Valeant in 2013. Dr. Waksal founded Kadmon Holdings, Inc. (NASDAQ: KDMN) in 2010 – a publicly traded New York City-based biopharmaceutical company focused on pioneering medicines in the areas of oncology, infectious diseases, immunology and metabolic diseases – serving as Chairman and Chief Executive Officer. He also founded Merlin (a core part of Somatix), one of the earliest gene-therapy companies.
Dr. Waksal spent the first half of his career in academic medicine. He was a professor of pathology and the director of the Division of Immunotherapy at the Mount Sinai School of Medicine in New York. He also served as visiting investigator at the National Cancer Institute, Immunology Branch, a research associate in the Department of Genetics at Stanford University Medical School, an assistant professor at Tufts University School of Medicine, and a senior scientist at the Tufts Cancer Research Center. Dr. Waksal was a scholar of the Leukemia Society of America, has been a visiting professor at the Pasteur Institute in France, as well as the Weizmann Institute of Science in Israel. He was also a member of the Board of Advisors of Rockefeller University. Dr. Waksal serves as a Visiting Fellow in Neuroscience at Weil Cornell Medical College, Feil Family Brain & Mind Research Institute in New York.
Dr. Waksal has published over 60 papers in such journals as Cell and Nature, as well as authoring chapters in biological texts. He is the recipient of numerous patents globally in the areas of cancer and immunology. For almost 15 years, Dr. Waksal served as the Chairman of the New York State Council for the Humanities at the behest of the Governor of New York State. Dr. Waksal has served as a board member for several public and private companies. He is also a regular guest host on CNBC’s Squawk Box.
Mr. Maisonrouge is Senior Managing Director Evercore’s Advisory business with 35 years of relevant experience. At Evercore, among other transactions, Mr. Maisonrouge was involved in advising AstraZeneca on its acquisition of Alexion, Sanofi on its acquisition of Principia, Nestlé on its sale of Nestlé Skin Health to EQT and ADIA, Bristol-Myers Squibb on its acquisition of Celgene, Takeda on its acquisition of Shire, AstraZeneca on its defense across from Pfizer, and Sun Pharmaceutical Industries on its acquisition of Ranbaxy Laboratories from Daiichi-Sankyo. In addition, Mr. Maisonrouge has been involved in a large number of IPOs and follow-on equity offerings, principally for biotech companies.
Prior to joining Evercore, Mr. Maisonrouge was a Managing Director and Chairman of Life Sciences at Credit Suisse where he worked extensively in the fields of pharmaceuticals, specialty pharmaceuticals, biotechnology and medical technology.
Mr. Maisonrouge holds an M.S. in Engineering from Ecole Centrale de Lyon and an M.B.A. from Harvard Business School. He is a member of the Board of Advisors of the Harvard Business School Health Care Initiative, and the Chairman of the Pasteur Foundation. In 2014, Mr. Maisonrouge was awarded the rank of Chevalier de la Légion d’Honneur.
Mr. Barach recently retired from Doubleline Capital, a $150 billion money management firm, where he was President and Co founder. He has over 43 years of experience in money management and finance in both the private and public sectors. He specialized in fixed income and his career spanned the highest and lowest interest rates in U.S. history.
Mr. Barach has substantial board experience. He served as vice chairman for Doubleline Funds since its inception in 2010 as well as Chief Executive Officer and vice chairman of Apex Mortgage Capital (AXM, NYSE).
Prior to founding Doubleline Mr. Barach spent 20 years at Trust Company of the West (TCW) where he was group managing director and CIO. He also was principal investment officer for the California Public Employees Retirement System ( PERS).
Mr. Barach is currently Chairman and Chief Executive Officer of Vista Investment Group, a privately held real estate investment firm.
Dr. Friedman is Managing Director and Senior Analyst at Averill, a therapeutics focused strategy within Suvretta Capital. Prior to joining Averill, Dr. Friedman was a Healthcare Analyst at Scopia Capital Management where he focused on biotechnology/specialty pharmaceutical companies and led the healthcare capital markets efforts including investing in IPOs and secondary offerings. Prior to Scopia, Dr. Friedman worked in biotechnology equity research at Morgan Stanley. Dr. Friedman’s experience also includes time at SAC Capital Advisors as a Healthcare Analyst. Dr. Friedman earned a BS degree in Biology from Duke University, received a M.D. from the University of Pittsburgh School of Medicine, performed general surgery residency training at the Massachusetts General Hospital, and obtained a MBA from Harvard Business School.
Mr. Gordon is Équilibre BioPharmaceuticals Corp.’s Chief Operating Officer; Chief Legal and Compliance Officer; and Corporate Secretary. Prior to joining Équilibre, Mr. Gordon co-founded Kadmon Holdings, Inc. (NASDAQ: KDMN) and served as its Executive Vice President; General Counsel; Chief Administrative, Legal and Compliance Officer; and Corporate Secretary.
Mr. Gordon worked as an Assistant District Attorney for the City of New York (Bronx County) before working at several NYC law firms and founding his own firm, which handled complex litigation for a broad spectrum of individual and corporate clients.
Mr. Gordon earned his B.A. in Economics and Business Administration from Bar Ilan University, and his J.D. from Touro College Jacob D. Fuchsberg Law Center. He is admitted to practice law before the state bars of New York and New Jersey, the District of Columbia, the United States Supreme Court and the United States District Courts for the Southern and Eastern Districts of New York.
Executive Chairman and Founder of Alexandria Real Estate Equities, Inc. (NYSE:ARE), the urban office REIT that pioneered life science real estate and today is the preeminent and longest-tenured owner, operator, and developer uniquely focused on collaborative life science, technology, and agtech campuses in AAA innovation cluster locations. Since co-founding the company in 1994 as a garage startup with $19 million in Series A capital, Mr. Marcus led Alexandria to its inclusion as an S&P 500 company, which has a total enterprise value of $33 billion, ranking it among the top 10 of all equity REITs, as well as a total equity capitalization of $24 billion and a total shareholder return exceeding 1,900% as of December 31, 2020.
Under Mr. Marcus’s leadership and through Alexandria’s critical role at the vanguard and heart of the life science ecosystem, the mission-driven company is building the future of life-changing innovation and driving positive change for the benefit of society. Mr. Marcus has guided Alexandria’s extraordinary growth through the tremendous execution of its visionary cluster campus strategy. Extending the company’s impact beyond its essential Labspace® real estate vertical, Mr. Marcus established three additional and complementary vertical platforms to enhance its holistic business model encompassing real estate, venture investments, thought leadership, and corporate responsibility.
During Mr. Marcus’s 27 years at Alexandria as a pioneer, entrepreneur, executive, and venture capitalist, he has helped form, build, and nurture a broad range of life science companies. Mr. Marcus founded and continues to lead Alexandria Venture Investments, the company’s strategic venture capital platform. Since its inception in 1996, it has invested in many of the most promising seed-, early-, and growth-stage companies advancing breakthroughs to meaningfully improve human health. With more than $1 billion under management, Alexandria Venture Investments is the most active biopharma venture capital investor in the nation.
In 2011, Mr. Marcus co-founded Alexandria’s thought leadership vertical with its signature initiative, the Alexandria Summit®. Over the last decade, the Alexandria Summit has helped stimulate novel approaches to disease that improve patient outcomes, drive the discovery and development of novel and cost-effective therapies, impact policy to advance innovation that saves lives and manages and cures disease, and address the urgent need to transform our healthcare system.
Mr. Marcus also leads Alexandria’s far-reaching social responsibility initiatives, which aim to drive forward disruptive and scalable solutions that address society’s most urgent and widespread challenges, including the COVID-19 pandemic, the opioid epidemic, poverty, and the educational achievement gap. To reverse the trajectory of the opioid crisis, Mr. Marcus and Alexandria partnered with Verily to pioneer OneFifteen, an innovative, non-profit evidence-based recovery ecosystem dedicated to helping people live healthy, addiction-free lives.
Prior to co-founding Alexandria, Mr. Marcus was one of the principal architects of Kirin-Amgen, Inc., the trailblazing biotech joint venture established in 1984 to fund the global development and commercialization of EPO (Epogen), and later G-CSF (Neupogen) — two blockbuster recombinant DNA products that have meaningfully benefited countless chronic kidney disease and cancer patients.
He earned his undergraduate and Juris Doctor degrees from the University of California, Los Angeles.
Mr. Simon is the Founder of Monsoon and Accessorize, which has grown from a single store in London’s Beauchamp Place in 1973 into two global fashion high street chains with a presence in more than 36 countries. The Group was a public company from 1998 to 2008, when it was taken private again. The company won the Queen’s Award for Export in 2007. In 1994 Mr. Simon founded The Monsoon Accessorize Trust, a registered charity that funds education, healthcare, and income generation projects primarily for disadvantaged women and children in Asia.
Having generated his wealth from fashion, Mr. Simon now backs a wide range of fast-growing businesses and talented areas in a number of sectors, spanning multiple sectors such as: biopharma; data technology; e-commerce; fashion and other direct to consumer; fin-tech; and thematic science development sectors such as ‘cultivated meat’ – where his investment vehicle, ‘Adena Estate Inc’, is often the lead, or majority investor.
The development of new pharmaceutical solutions to serious medical conditions is something that Mr. Simon feels passionately about and Adena’s investment in Équilibre is the latest such investment.
Away from private equity, Mr. Simon also has a substantial portfolio of commercial property centred primarily in London’s fashionable Notting Hill, W11. Amongst these properties is The Electric Cinema on Portobello Road, where Mr. Simon restored the oldest purpose-built cinema in England, and which is now managed by the highly successful global restaurant and members' club group, Soho House.
Mr. Simon’s other passion is in the arts, where he has identified and supported many emerging artists. His collection is especially known for its holdings of works from Central and South America, Africa, and Asia. In addition, Mr. Simon is an honorary trustee of the Tate Foundation, which manages Britain’s Tate galleries, as well as being a member of the Global Patrons Council for Art Basel.